Name: Inebilizumab
SKU: AP15506
Availability: InStock

Inebilizumab

$230.00 – $955.00

Inebilizumab (CAS 1299440-37-1) is a monoclonal antibody that targets CD19 on B cells. It depletes B cells to treat autoimmune diseases like neuromyelitis optica spectrum disorder (NMOSD) and is being studied for other autoimmune conditions.

Unit

Price

Quantity

1 mg

$230

5 mg

$595

10 mg

$955

Would you like to inquire about bulk pricing?

Inebilizumab (CAS 1299440-37-1) is a humanized monoclonal antibody that targets CD19, a protein found on B cells. It works by depleting B cells, which are involved in autoimmune diseases. This makes inebilizumab useful for treating neuromyelitis optica spectrum disorder (NMOSD), a condition affecting the central nervous system.

Key Features:

Target Specificity: Binds to CD19 on B cells.
Mechanism of Action: Reduces autoimmune activity by depleting B cells.
Molecular Characteristics: Humanized IgG1 monoclonal antibody.

Applications:

NMOSD Treatment: Treats NMOSD in adults who test positive for anti-aquaporin-4 antibodies.
Autoimmune Conditions: Being studied for other autoimmune diseases.
In ADCs: Inebilizumab targets CD19 on B cells, delivering cytotoxic drugs directly to cancer cells. This approach helps reduce toxicity and improve treatment effectiveness, particularly for B-cell-related cancers.

AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.